Menu
Recruiting NCT06331130

Mesenteric Infiltration in Ovarian Cancer

Observational Ovary Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Computed Tomography.
Who it may be relevant to
Registry conditions: Ovary Cancer. Basic parameters: from 18 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

CT Detected Tumour Infiltration Patterns of the Mesentery in High Grade Ovarian Carcinoma (HGSOC) Patients, Their Role in Treatment Planning and Outcome Prediction and How Machine Learning Can be Applied to Identify Them.

Overview

To evaluate if CT features at diagnosis in patients with HGSOC can be used to build an Artificial Intelligence model capable of discerning the pathological involvement of the mesentery, assessing the potential impediments for an optimal debulking surgery and predicting the development of resistance to platinum based chemotherapeutic agents.

Interventions

  • Diagnostic test Computed Tomography
    Computed Tomography done according to Clinical Practice to assess mesenteric involvment

Primary outcome measures

  • Preoperative Artificial Intelligence assisted CT-based evaluation [Time frame: 1 year]
Secondary outcome measures (3)
  • Evaluation of the Radiologist Assessment of the CT [Time frame: 1 year]
  • Prediction of Platinum Resistance [Time frame: 1 year]
  • Prediction of Progression Free Survival (PFS) and Overall Survival (OS) [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • Women with confirmed HGSOC wiht mesenteric involvment
  • Age > 18 years
  • FIGO STAGE IIIB-IV
  • Primary diagnosis
  • Signed informed consent

Exclusion criteria

  • Non-serous high grade epithelial ovarian cancer (serous low grade, mucinous, clear cell carcinoma, endometrioid or non-epithelial ovarian cancer)
  • Early stage disease (I and II stage)
  • CT scan not available
  • Non-primary diagnosis or patient subjected to neoadjuvant chemotherapy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Other

Study locations

Italy · 1 center
  • Advanced Radiology Center — Roma

Identifiers

NCT: NCT06331130 · 6363

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗